SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):136P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Weiler-Sagie, M.
Right arrow Articles by Israel, O.
PubMed
Right arrow Articles by Weiler-Sagie, M.
Right arrow Articles by Israel, O.

General Clinical Specialties: General Practice-Oncology

Lymphoma

FDG-avidity of lymphoma subtypes – A study of 501 patients

Michal Weiler-Sagie1, Rachel Bar-Shalom1, Zohar Keidar1 and Ora Israel1

1 Rambam Health Care Campus, Haifa, Israel

540

Objectives: FDG-PET/CT is an important tool for management of lymphoma. The presence and degree of FDG uptake in lymphoma of various histologies has been previously assessed in small number of patients (pts). Present study aims at defining FDG-avidity for different lymphoma subtypes according to the World Health Organization (WHO) classification in a large cohort of pts.

Methods: FDG-PET/CT studies performed for staging in 501 pts with newly diagnosed lymphoma were retrospectively reviewed for the presence of abnormal FDG uptake in at least one site of disease. Histology was confirmed in all pts and defined according to the WHO classification.

Results: At least one FDG-avid lymphoma site was detected in 482 pts (96%). FDG-avidity was found in all pts (100%) with Hodgkin lymphoma (HL; n=177), and in 94% pts with non-Hodgkin lymphoma (NHL: n=305/324) including: all pts with Burkitt and Burkitt-like lymphoma (BL; n=13) and nodal marginal zone B-cell lymphoma (nMZL; n=6), 99% pts with diffuse large B-cell lymphoma (LBCL; n=136/138), 96% pts with follicular lymphoma (FL; n=82/85), 90% pts with T-cell lymphoma (TCL; n=26/29), 84% pts with small lymphocytic lymphoma (SLL; n=16/19), and 68% pts with extranodular MZL (eMZL; n=17/25). Of the 19 pts with non-FDG avid lymphoma 16 pts (84%) showed extranodal disease involving the stomach (6), skin (7), tracheal and buccal mucosa (2) and small bowel (1), and 3 pts had nodal SLL.

Conclusions: FDG-avidity was found in 96% pts in this large study group including numerous histological subtypes of lymphoma. FDG-PET/CT can be therefore used as a reliable tool in clinical management of most lymphoma pts. Lower detection rates were found in eMZL and SLL, and in lymphoma of the skin which appears to be less detectable regardless of its specific histology.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Weiler-Sagie, M.
Right arrow Articles by Israel, O.
PubMed
Right arrow Articles by Weiler-Sagie, M.
Right arrow Articles by Israel, O.